Altimmune to participate in multiple investor conferences for one-on-one meetings and fireside chats discussing pemvidutide's development.
Quiver AI Summary
Altimmune, Inc., a biopharmaceutical company focused on therapies for serious liver diseases, announced its participation in several upcoming investor conferences. Management will hold one-on-one meetings at the Leerink Global Healthcare Conference on March 9, Citizens Life Sciences Conference on March 10, Jefferies Biotech on the Beach Summit on March 11, and Barclays Global Healthcare Conference on March 12. Additionally, Altimmune will host fireside chats on March 11 and March 12, which will be available for viewing via their website. The company is developing pemvidutide, a dual-action therapy for metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. Investors are invited to request meetings through their sales contacts.
Potential Positives
- Altimmune is actively engaging with investors through participation in multiple significant healthcare conferences, which can enhance visibility and attract interest in their clinical developments.
- The company is presenting its lead candidate, pemvidutide, targeting serious liver diseases, indicating a focused and promising development pipeline.
- The structured format of one-on-one meetings and fireside chats demonstrates Altimmune's proactive approach to investor relations and communication.
- Webcasts of the fireside chats provide an opportunity for broader audience engagement beyond in-person attendees, increasing the potential reach of their messaging.
Potential Negatives
- The press release does not provide any updates on clinical trial results or progress for pemvidutide, which may raise concerns regarding the timeline and effectiveness of the drug development.
- The company's focus on investor meetings rather than scientific breakthroughs may suggest a lack of significant advancements in their research, potentially indicating stagnation.
- The mention of investor conferences without showcasing a new partnership or funding could imply financial vulnerability or the need for external support.
FAQ
What is pemvidutide developed by Altimmune?
Pemvidutide is a dual-action therapy targeting glucagon and GLP-1 receptors for serious liver diseases.
When will Altimmune participate in investor conferences?
Altimmune will participate in various investor conferences from March 9 to March 12, 2026.
How can investors request meetings with Altimmune?
Registered investors can request meetings through their sales contacts at the respective banks during the conference dates.
Where can I watch the fireside chats?
Webcasts of the fireside chats will be available in the Events section on Altimmune's website.
What liver diseases is pemvidutide targeting?
Pemvidutide is in development for metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALT Insider Trading Activity
$ALT insiders have traded $ALT stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ALT stock by insiders over the last 6 months:
- JEROME BENEDICT DURSO purchased 12,500 shares for an estimated $51,568
- JOHN GILL purchased 12,500 shares for an estimated $51,249
- WAYNE PISANO purchased 5,000 shares for an estimated $20,410
- DIANE JORKASKY purchased 527 shares for an estimated $2,002
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ALT Hedge Fund Activity
We have seen 121 institutional investors add shares of $ALT stock to their portfolio, and 83 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 3,331,039 shares (+52.3%) to their portfolio in Q4 2025, for an estimated $12,025,050
- VANGUARD GROUP INC added 3,117,521 shares (+48.9%) to their portfolio in Q4 2025, for an estimated $11,254,250
- STATE STREET CORP added 1,518,448 shares (+42.2%) to their portfolio in Q4 2025, for an estimated $5,481,597
- JANE STREET GROUP, LLC added 1,503,751 shares (+536.7%) to their portfolio in Q4 2025, for an estimated $5,428,541
- NUVEEN, LLC added 1,041,856 shares (+514.9%) to their portfolio in Q4 2025, for an estimated $3,761,100
- D. E. SHAW & CO., INC. added 983,188 shares (+272.8%) to their portfolio in Q4 2025, for an estimated $3,549,308
- MARSHALL WACE, LLP added 922,777 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,331,224
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ALT Analyst Ratings
Wall Street analysts have issued reports on $ALT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citizens issued a "Market Outperform" rating on 11/07/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/10/2025
To track analyst ratings and price targets for $ALT, check out Quiver Quantitative's $ALT forecast page.
$ALT Price Targets
Multiple analysts have issued price targets for $ALT recently. We have seen 2 analysts offer price targets for $ALT in the last 6 months, with a median target of $13.0.
Here are some recent targets:
- Jonathan Wolleben from Citizens set a target price of $14.0 on 11/07/2025
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $12.0 on 10/20/2025
Full Release
GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences:
-
Leerink Global Healthcare Conference
Monday, March 9, 2026 – One-on-one meetings
Wednesday, March 11, 2026 – Fireside chat at 9:20 a.m. ET
-
Citizens Life Sciences Conference
Tuesday, March 10, 2026 – One-on-one meetings
Fireside chat at 2:15 p.m. ET
-
Jefferies Biotech on the Beach Summit
Wednesday, March 11, 2026 – One-on-one meetings only
-
Barclays 28
th
Annual Global Healthcare Conference
Thursday, March 12, 2026 – One-on-one meetings
Fireside chat at 10:30 a.m. ET
Webcasts of the fireside chats at the Leerink, Citizens and Barclays conferences will be available via the Events section of the Altimmune website.
Registered investors may request meetings on the dates noted above via their sales contacts at the respective banks.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit
www.altimmune.com
.
Follow @Altimmune, Inc. on
LinkedIn
Follow @AltimmuneInc on
X
Investor Contact:
Lee Roth
Burns McClellan
[email protected]
Media Contact:
Real Chemistry
[email protected]
This press release was published by a CLEAR® Verified individual.
